SLEIPNIR Clinical Trial Platform To Test 3 Parkinson’s Drugs At Once

Cure Parkinson’s is funding SLEIPNIR, a multiarm clinical trial platform that will simultaneously test up to three disease-modifying treatments for Parkinson’s disease — assessing whether any of them can engage with their intended targets in the brain.

The results are expected to help decide if these treatments should enter late-stage efficacy trials, according to a press release from the nonprofit. The hope, Cure Parkinson’s noted, is that SLEIPNIR will reduce the risk of drugs failing in larger-scale trials by testing several medications at once against the same placebo group in a smaller study with a shorter time frame.